Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968942 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
A Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00968942: Completed Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, sponsored by Revance Therapeutics.
NCT00968942 is a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines that has completed, run by Revance Therapeutics. The registered enrollment target is 36 participants, below the 81-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00968942, a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin Type A
Study Locations (1)
Florida
- Dermatology Research Institute, LLC. - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00968942 record still lists
NCT00968942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 81-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (56% lower).
The record links to 3 conditions, with Facial Wrinkles appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00968942 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00968942 about?
NCT00968942 is a clinical study titled "Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines". The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
What is the current status of trial NCT00968942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2009-08. Estimated completion is 2009-10.
What conditions does trial NCT00968942 study?
This clinical trial studies the following conditions: Facial Wrinkles, Lateral Canthal Lines, Crows Feet.
What interventions are being tested in trial NCT00968942?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT00968942?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00968942 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facial Wrinkles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryo-Touch II for the Treatment of Wrinkles
COMPLETED · Phase 2
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
COMPLETED · Phase 2
-
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
COMPLETED · Phase 2
-
Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles
COMPLETED · NA
-
A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)
COMPLETED · Phase 3
-
PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia